Respiratory syncytial virus and seasonal influenza cause similar illnesses in children with sickle cell disease.

Related Articles

Respiratory syncytial virus and seasonal influenza cause similar illnesses in children with sickle cell disease.

Pediatr Blood Cancer. 2014 Jan 31;

Authors: Sadreameli SC, Reller ME, Bundy DG, Casella JF, Strouse JJ

Abstract
BACKGROUND: Respiratory syncytial virus (RSV) is a cause of acute chest syndrome (ACS) in sickle cell disease (SCD), but its clinical course and acute complications have not been well characterized. We compared RSV to seasonal influenza infections in children with SCD.
PROCEDURE: We defined cases as laboratory-confirmed RSV or seasonal influenza infection in inpatients and outpatients <18 years of age with SCD from 1 September 1993 to 30 June 2011. We used Fisher’s exact test to compare proportions, Student’s t-test or Wilcoxon rank-sum test to compare continuous variables, and logistic regression to evaluate associations.
RESULTS: We identified 64 children with RSV and 91 with seasonal influenza. Clinical symptoms, including fever, cough, and rhinorrhea were similar for RSV and influenza, as were complications, including ACS and treatments for SCD. In a multivariable logistic regression model, older age (OR 1.2 per year, 95% CI [1.02-1.5], P?=?0.04), increased white blood cell count at presentation (OR 1.1 per 1,000/?l increase, 95% CI [1.03-1.3], P?=?0.008), and a history of asthma (OR 7, 95% [CI 1.3-37], P?=?0.03) were independently associated with increased risk of ACS in children with RSV. The hospitalization rate for children with SCD and RSV (40 per 1,000 <5 years and 63 per 1,000 <2 years) greatly exceeds the general population (3 in 1,000 <5 years).
CONCLUSIONS: We conclude that RSV infection is often associated with ACS and similar in severity to influenza infection in febrile children with SCD. Pediatr Blood Cancer 2014;9999:1-4. © 2014 Wiley Periodicals, Inc.

PMID: 24481883 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

AstraZeneca Symbicort shows similar safety profile as Budesonide for asthma – Pharmaceutical Business Review

AstraZeneca Symbicort shows similar safety profile as Budesonide for asthma
Pharmaceutical Business Review
AstraZeneca has published a new study that demonstrates that Symbicort Inhalation Aerosol 320/9 µg twice daily has a safety profile similar to Budesonide pressurized metered-dose inhaler (pMDI) 320 µg twice daily for asthma.
SYMBICORT® (budesonide/formoterol fumarate dihydrate) Long-Term Study Shows EON: Enhanced Online News (press release)

all 2 news articles »

View full post on asthma – Google News